Get the Stockscreener App
0.6601
1.49%
-0.01
Pre-market:
.69
0.0299
+4.53%
Enlivex Ltd stock is traded at $0.6601, with a volume of 305.13K.
It is down -1.49% in the last 24 hours and down -8.40% over the past month.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.
See More
Previous Close:
$0.6701
Open:
$0.7073
24h Volume:
305.13K
Relative Volume:
0.52
Market Cap:
$159.12M
Revenue:
-
Net Income/Loss:
$1.24B
P/E Ratio:
0.0259
EPS:
25.475
Net Cash Flow:
$-31.80M
1W Performance:
-7.57%
1M Performance:
-8.40%
6M Performance:
-23.33%
1Y Performance:
-26.66%
1-Day Range:
$0.65
$0.7073
1-Week Range:
$0.65
$0.7538
52-Week Range:
$0.65
$2.10
Enlivex Ltd Stock (ENLV) Company Profile
Compare ENLV vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENLV
Enlivex Ltd
|
0.6601 | 159.12M | 0 | 1.24B | -31.80M | 25.48 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Enlivex Ltd Stock (ENLV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-21 | Reiterated | H.C. Wainwright | Buy |
Enlivex Ltd Stock (ENLV) Latest News
Enlivex Secures Australian Patent for Allocetra in Osteoarthritis Treatment - GuruFocus
Enlivex receives Australian patent for osteoarthritis treatment - Investing.com
Enlivex Announces Issuance of Australian Patent Covering the Use of Allocetra™ in Patients with Osteoarthritis - The Manila Times
ENLV Q4 2025 Earnings: Deep Losses and Clinical Progress Amid Severe EPS MissEarnings Revision Upgrade - newsline.com
Enlivex Therapeutics stock (IL0011283620): Data monitoring, Nasdaq notice and next steps for investo - AD HOC NEWS
ENLV Q4 2025 Earnings: Significant EPS Miss Reflects Clinical-Stage DevelopmentHigh Estimate Range - newsline.com
Number of shareholders of Enlivex Ltd. – LSX:A119KH - TradingView
RAIN Highlights $200M Ecosystem Commitment, $100M Liquidity Expansion, and World Cup Growth Strategy Ahead of Version 2 Launch - GlobeNewswire Inc.
ENLIVEX TO PRESENT QUALITY LONGEVITY MODEL POWERED BY PREDICTION MARKETS TREASURY AT PROOF OF TALK 2026 - marketscreener.com
Enlivex brings longevity‑prediction markets pitch to $18T Paris summit - Stock Titan
Enlivex to present knee osteoarthritis trial data at EULAR By Investing.com - Investing.com South Africa
Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026 - The Manila Times
Enlivex to present knee osteoarthritis trial data at EULAR - Investing.com
Experimental cell therapy eases knee arthritis pain for 6 months - Stock Titan
Enlivex Values RAIN Token Treasury at $1.16 Billion as Rain Protocol Climbs to No. 3 in Prediction Markets - The Globe and Mail
Enlivex (ENLV) Tests Key Support at $0.72 as Downtrend IntensifiesImbalance Zone - The Legal Advocate
Enlivex's RAIN tokens valued at $1.16B as Rain protocol ranks 3rd in global prediction markets. - Pluang
Enlivex reports $1.16 billion in RAIN token holdings - Investing.com UK
Enlivex reports $1.16 billion in RAIN token holdings By Investing.com - Investing.com India
Enlivex Highlights $100M Liquidity Boost for Rain as Treasury-Backed Prediction Market Enters Global Top Three - The Globe and Mail
Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.16 Billion; Rain Foundation Appoints Industry Leaders to Advisory Board - The Manila Times
RAIN treasury hits $1.16B as Enlivex (Nasdaq: ENLV) details prediction markets push - Stock Titan
Enlivex Ltd. (ENLV) Rallies 14%: Key Levels and Technical OutlookBPI Reversal - The Legal Advocate
Enlivex Highlights Rain Foundation's $100M Commitment - GuruFocus
Enlivex (NASDAQ: ENLV) details $100M Rain liquidity and massive RAIN token holdings - Stock Titan
Enlivex Treasury Portfolio Update: Rain Protocol Jumps Into Top Three Global Prediction Markets In League Table Following $100M In Additional Liquidity - marketscreener.com
$100M liquidity push lifts Rain into top 3 prediction markets - Stock Titan
Enlivex Surges 12.87% as Biotech Stock Breaks Above Key Support LevelsCTA Positioning - newsline.com
Enlivex (ENLV) Shares Slide 4.67% as Stock Tests Key Support at $0.65Ichimoku Entry - Newser
ENLV Q4 2025 Earnings: Significant EPS Miss Amid Development Stage CostsROE Trend Analysis - The Legal Advocate
Enlivex Ltd. (ENLV) Slides Slightly as Shares Hover Near Key Support LevelFast Moving Stocks - thelegaladvocate.com
Enlivex Ltd expected to post a loss of 2 cents a shareEarnings Preview - TradingView
Enlivex (ENLV) Edges Higher After Testing Key Support at $0.69Ichimoku TK Cross - Newser
ENLV Q1'26 Earnings: EPS estimate is (0.02) USD - TradingView
Enlivex Therapeutics Initiates Phase 2b Trial in US, Doses First Patient with Allocetra for Knee Osteoarthritis - geneonline.com
Enlivex Doses First US Patient in Phase 2b Knee Osteoarthritis Trial - Moomoo
Enlivex (ENLV) Begins Phase 2b Clinical Trial for Osteoarthritis Treatment - GuruFocus
Enlivex doses first U.S. patient in knee osteoarthritis trial - Investing.com UK
Enlivex doses first U.S. patient in knee osteoarthritis trial By Investing.com - Investing.com South Africa
Enlivex Doses First U.S. Patient in Phase 2b Allocetra Trial for Knee Osteoarthritis - TipRanks
Enlivex Ltd Stock (ENLV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):